Jul 27, 2026
ICMR licenses cervical cancer drug SHetA2 to Emcure Pharmaceuticals for development in India
India's ICMR has licensed SHetA2, an experimental drug that aims to prevent HPV from turning cancerous, to Emcure Pharmaceuticals for development. The move addresses India's significant cervical cancer burden, with approximately 123,907 new cases and 77,348 deaths annually.
3 sources
00